CRSP insider transaction filings
CRISPR Therapeutics AG — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-11. Screen CRSP transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-11 | 4 | Prasad Raju — Chief Financial Officer | Gift (G): 750 @ $0 | EDGAR |
| 2026-06-09 | 4 | Fleming Harold Edward — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Rommel Christian — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Treco Douglas A — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Morrison Briggs — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | High Katherine A — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Behbahani Ali — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Greene John — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | George Simeon — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Fardis Maria — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Mahatme Sandesh — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | KASINGER JAMES R. — General Counsel and Secretary | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Patel Naimish — Chief Medical Officer | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Prasad Raju — Chief Financial Officer | Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Patel Naimish — Chief Medical Officer | Option exercise (M): 10,000 · Sale (S): 3,786 @ $55.62 · Option exercise (M): 10,000 (derivative) | EDGAR |
| 2026-03-24 | 4 | KASINGER JAMES R. — General Counsel and Secretary | Option exercise (M): 6,250 · Sale (S): 3,182 @ $46.78 · Grant/award (A): 38,499 (derivative) @ $0 · Grant/award (A): 25,000 (derivative) @ $0 · Option exercise (M): 6,250 (derivative) | EDGAR |
| 2026-03-24 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Option exercise (M): 19,687 · Sale (S): 10,020 @ $46.78 · Grant/award (A): 114,249 (derivative) @ $0 · Grant/award (A): 81,875 (derivative) @ $0 · Option exercise (M): 19,687 (derivative) | EDGAR |
| 2026-03-24 | 4 | Prasad Raju — Chief Financial Officer | Option exercise (M): 6,250 · Sale (S): 3,708 @ $46.78 · Grant/award (A): 38,499 (derivative) @ $0 · Grant/award (A): 27,500 (derivative) @ $0 · Option exercise (M): 6,250 (derivative) | EDGAR |
| 2026-03-24 | 4 | Patel Naimish — Chief Medical Officer | Grant/award (A): 38,499 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Patel Naimish — Chief Medical Officer | Option exercise (M): 8,125 · Sale (S): 3,150 @ $48.26 · Option exercise (M): 8,125 (derivative) | EDGAR |
| 2026-03-17 | 4 | Prasad Raju — Chief Financial Officer | Option exercise (M): 10,000 · Option exercise (M): 6,875 · Sale (S): 5,848 @ $48.26 · Sale (S): 4,021 @ $48.26 · Gift (G): 750 @ $0 · Option exercise (M): 10,000 (derivative) · +1 more | EDGAR |
| 2026-03-17 | 4 | KASINGER JAMES R. — General Counsel and Secretary | Option exercise (M): 6,875 · Sale (S): 3,450 @ $48.26 · Option exercise (M): 6,875 (derivative) | EDGAR |
| 2026-03-17 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Option exercise (M): 20,625 · Sale (S): 10,349 @ $48.26 · Option exercise (M): 20,625 (derivative) | EDGAR |
| 2026-03-12 | 4 | KASINGER JAMES R. — General Counsel and Secretary | Option exercise (M): 5,500 · Sale (S): 2,800 @ $52.80 · Option exercise (M): 5,500 (derivative) | EDGAR |
| 2026-03-12 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Option exercise (M): 19,250 · Sale (S): 9,798 @ $52.80 · Option exercise (M): 19,250 (derivative) | EDGAR |
| 2026-02-20 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Option exercise (M): 13,250 · Sale (S): 6,967 @ $52.58 · Option exercise (M): 13,250 (derivative) | EDGAR |
| 2026-02-20 | 4 | KASINGER JAMES R. — General Counsel and Secretary | Option exercise (M): 3,825 · Sale (S): 2,112 @ $52.58 · Option exercise (M): 3,825 (derivative) | EDGAR |
| 2026-01-27 | 4 | Patel Naimish — Chief Medical Officer | Purchase (P): 1,508 @ $32.96 | EDGAR |
| 2026-01-26 | 4 | Prasad Raju — Chief Financial Officer | Option exercise (M): 34,972 @ $45.15 · Sale (S): 34,972 @ $60.19 · Option exercise (M): 34,972 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Sale (S): 21,433 @ $51.61 · Sale (S): 8,567 @ $52.10 · Sale (S): 60,000 @ $60.23 | EDGAR |
| 2026-01-08 | 4 | Prasad Raju — Chief Financial Officer | Option exercise (M): 23,361 @ $45.15 · Option exercise (M): 6,339 @ $44.31 · Sale (S): 18,933 @ $60.18 · Sale (S): 5,004 @ $60 · Sale (S): 5,763 @ $60.21 · Option exercise (M): 23,361 (derivative) @ $0 · +1 more | EDGAR |
| 2025-12-23 | 4 | Prasad Raju — Chief Financial Officer | Sale (S): 3,528 @ $55.10 · Sale (S): 5,472 @ $56.33 · Sale (S): 1,000 @ $56.89 | EDGAR |
| 2025-12-22 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Gift (G): 30,000 @ $0 | EDGAR |
| 2025-10-20 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Option exercise (M): 100,000 · Sale (S): 50,895 @ $67.91 · Option exercise (M): 100,000 (derivative) | EDGAR |
| 2025-10-15 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Option exercise (M): 8,334 · Sale (S): 4,242 @ $66.60 · Option exercise (M): 8,334 (derivative) | EDGAR |
| 2025-10-15 | 4 | KASINGER JAMES R. — General Counsel and Secretary | Option exercise (M): 2,114 · Sale (S): 1,076 @ $66.60 · Option exercise (M): 2,114 (derivative) | EDGAR |
| 2025-10-03 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Grant/award (A): 49,500 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | Patel Naimish — Chief Medical Officer | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | KASINGER JAMES R. — General Counsel and Secretary | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2025-10-03 | 4 | Prasad Raju — Chief Financial Officer | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2025-09-19 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Gift (G): 6,000 @ $0 | EDGAR |
| 2025-08-19 | 4 | Kulkarni Samarth — Chief Executive Officer, Director | Option exercise (M): 25,000 · Sale (S): 13,081 @ $58.15 · Option exercise (M): 25,000 (derivative) | EDGAR |
| 2025-08-08 | 4 | Treco Douglas A — Director | Purchase (P): 20,000 @ $57.03 | EDGAR |
| 2025-07-17 | 4 | George Simeon — Director | Purchase (P): 6,510 @ $52.03 · Purchase (P): 22,319 @ $52.03 · Purchase (P): 960,983 @ $52.03 | EDGAR |
| 2025-06-06 | 4 | Treco Douglas A — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Rommel Christian — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Fleming Harold Edward — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Morrison Briggs — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | High Katherine A — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Behbahani Ali — Director | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — CRISPR Therapeutics AG
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-11 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CRSP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →